✦ LIBER ✦

Dopamine agonist pretreatment alters LSD's electrophysiological action from dopamine agonist to antagonist

✍ Scribed by Greg R. Christoph; Donald M. Kuhn; Barry L. Jacobs

Book ID: 118938346
Publisher: Elsevier Science
Year: 1978
Tongue: English
Weight: 654 KB
Volume: 23
Category: Article
ISSN: 0024-3205
DOI: 10.1016/0024-3205(78)90183-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The dopamine receptor: Differential bind

The dopamine receptor: Differential binding of d-LSD and related agents to agonist and antagonist states

✍ Ian Creese; David R. Burt; Solomon H. Snyder 📂 Article 📅 1975 🏛 Elsevier Science 🌐 English ⚖ 301 KB

Selectivity of agonists and antagonists

Selectivity of agonists and antagonists at D2dopamine receptors compared to D1 and S2receptors

✍ Dr. Philip Seeman; Dimitri E. Grigoriadis; Hyman B. Niznik 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB

Seeman, P., D.E. Grigoriadis, and H.B. Niznik: Selectivity of agonists and antagonists at D2 dopamine receptors compared to D, and S2 receptors. Drug Dev. Res. 9:63-69, ## 1986. The common dopamine agonists (dopamine, apomorphine, ADTN, and N-propylnorapomorphine) are not selective for either D,

Usefulness of switching to cabergoline f

Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson’s disease

✍ M. Shiraishi; T. Kamo; M. Hotta; S. Nemoto; J. Oshima; H. Sugihara; S. Yasaki; M 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 106 KB

A history of dopamine agonists. From the

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson’s disease – a subjective view

✍ R. Horowski 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 133 KB

The actions of (−)N-n-propylnorapomorphi

The actions of (−)N-n-propylnorapomorphine and selective dopamine D1 and D2 receptor agonists to modify the release of [3H]dopamine from the rat nucleus accumbens

✍ J.M. Barnes; N.M. Barnes; B. Costall; R.J. Naylor 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 957 KB

Switching from ergot to nonergot dopamin

Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table

✍ Katherine Grosset; Fiona Needleman; Graeme Macphee; Donald Grosset 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

## Abstract Of 99 patients on ergot‐derived dopamine agonists informed about possible long‐term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%. After 11 months, 82% were on their switch agonist and 93% were on any agonist. Switching dopamine agoni